This page shows the latest Versartis news and features for those working in and with pharma, biotech and healthcare.
The US biotech's somavaratan proved inferior to Pfzier’s Genotropin. US biotech Versartis saw more than 80% wiped off its share price ahead of the weekend after its growth hormone ... Versartis disappointment has proved a fillip for rival company
Also in the running is Versartis, whose somavaratan (VRS-317) is in late-stage trials and was recently licensed to Teijin in Japan.
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
252. Versartis. Teijin (JP). Licence Japan. Somavaratan, long-acting form of rhGH, for paediatric and adult growth hormone deficiency in phase II/III in Japan.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Joshua Brumm joins from Pharmacyclics. Versartis has named Joshua Brumm as its first chief financial officer. ... The company's CEO Dr Jeffrey Cleland said: "His appointment comes during a particularly exciting stage of development for Versartis and will
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...